Loading clinical trials...
Loading clinical trials...
This is a first-in-human,randomized, double-blind, placebo-controlled, single dose escalation, phase 1 study to evaluate the safety, tolerability, PK/PD and immunogenicity of AK102 administered subcut...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Akeso
Collaborators
NCT02693548 · Familial Hypercholesterolaemia
NCT05621070 · Primary Hypercholesterolaemia and Mixed Dyslipidemia
NCT06646354 · Hypertension, Primary Hypercholesterolaemia
NCT05934292 · Hypercholesterolaemia
NCT04507984 · Familial Hypercholesterolemia, Polygenic Hypercholesterolaemia
Peking Union Medical College Hospital
Beijing
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions